Edition:
United States

INSYS Therapeutics Inc (INSY.O)

INSY.O on Consolidated Issue listed on NASDAQ Global Market

0.88USD
24 May 2019
Change (% chg)

$0.06 (+7.12%)
Prev Close
$0.82
Open
$0.85
Day's High
$0.92
Day's Low
$0.83
Volume
965,216
Avg. Vol
1,186,743
52-wk High
$11.65
52-wk Low
$0.79

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

  INSY.O Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.21 -- --
ROI: -5.71 8.91 13.82
ROE: -5.88 10.05 15.25

Insys says it may be forced to file for bankruptcy due to litigation cash crunch

Insys Therapeutics Inc said on Friday that a cash crunch resulting from legal costs related to a U.S. Justice Department probe into sales practices for the company's powerful opioid medication and other litigation may lead the company to file for bankruptcy and prevent it from completing its settlement deal with the Justice Department.

May 11 2019

Insys says it may be forced to file for bankruptcy due to litigation cash crunch

May 10 Insys Therapeutics Inc said on Friday that a cash crunch resulting from legal costs related to a U.S. Justice Department probe into sales practices for the company's powerful opioid medication and other litigation may lead the company to file for bankruptcy and prevent it from completing its settlement deal with the Justice Department.

May 10 2019

Founder, execs of drug company guilty in conspiracy that fed opioid crisis

BOSTON The founder of Insys Therapeutics Inc on Thursday became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.

May 02 2019

UPDATE 6-Founder, execs of drug company guilty in conspiracy that fed opioid crisis

BOSTON, May 2 The founder of Insys Therapeutics Inc on Thursday became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.

May 02 2019

Former Insys manager unfairly charged due to lap dance, lawyer argues

A lawyer for an ex-stripper who became a regional sales director at Insys Therapeutics Inc argued on Friday that prosecutors had unfairly pulled her into the prosecution of much more senior company executives accused of bribing physicians to prescribe opioids because of an allegation that she gave a doctor a lap dance.

Apr 05 2019

Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor

BOSTON The founder of Insys Therapeutics Inc put profits over patient safety by bribing doctors to prescribe an addictive fentanyl spray, fueling the U.S. opioid epidemic, a federal prosecutor said on Thursday at the end of a landmark trial.

Apr 04 2019

UPDATE 2-Drug company founder, execs exploited patients to sell opioid -U.S. prosecutor

BOSTON, April 4 The founder of Insys Therapeutics Inc put profits over patient safety by bribing doctors to prescribe an addictive fentanyl spray, fueling the U.S. opioid epidemic, a federal prosecutor said on Thursday at the end of a landmark trial.

Apr 04 2019

U.S. to wrap case against drug company executives tied to opioid crisis

BOSTON, April 4 Prosecutors on Thursday will present their closing arguments in the trial of the wealthy founder of pharmaceutical company Insys Therapeutics Inc and four colleagues accused of contributing to the U.S. opioid epidemic by bribing doctors to prescribe an addictive fentanyl spray.

Apr 04 2019

Insys Therapeutics' auditor raises going concern doubts, shares drop

Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent.

Mar 13 2019

UPDATE 1-Insys Therapeutics' auditor raises going concern doubts, shares drop

March 13 Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent.

Mar 13 2019

Earnings vs. Estimates